-

Mirion Medical Introduces Instadose®VUE Dosimeter at Radiological Society of North America (RSNA) Annual Meeting

Innovative Solutions for Diagnostic Imaging QA, Nuclear Medicine, & Medical Imaging Tables Also Featured for Mirion Medical at RSNA

ATLANTA--(BUSINESS WIRE)--Mirion (“we” or “the company”), announced today that it will debut the new Instadose®VUE personal dosimeter, from its Dosimetry Services brand, at the 2023 Radiological Society of North America (RSNA) Meeting starting Sunday in Chicago, Illinois. Mirion Dosimetry Services joins Sun Nuclear, Capintec, and Biodex medical imaging brands in the Mirion Medical booth (#6328) at RSNA, which will feature products and services for occupational dosimetry, diagnostic imaging QA, nuclear medicine, and medical imaging tables and accessories.

Introducing the InstadoseVUE Personal Dosimeter

The new Instadose®VUE advanced, wireless personal dosimeter offers a display screen for improved user engagement, insights, and compliance. Harnessing Bluetooth® Low Energy Technology, the InstadoseVUE dosimeter enables wearers to capture personalized dose reads on-demand, anytime and anywhere. With programmable calendar features, scheduling automatic dose reads ahead of time is easy, simplifying dose reporting and management even further.

Highlights for the Mirion Medical Booth

Other industry-leading solutions featured at the Mirion Medical booth include:

  • IQphan™ Phantom for comprehensive CT QA (Sun Nuclear)
  • RapidCHECK™ Analysis Software (Sun Nuclear)
  • Captus® 4000e Thyroid Uptake System (Capintec)
  • CRC® Dose Calibrators and Well Counters (Capintec)
  • Surgical C-Arm Table – 840 (Biodex)
  • Sound Pro™ Combination Table (Biodex)

Mirion Medical experts will be on hand to provide product insights and demonstrations.

ec² Software Solutions, Now Part of Mirion Medical

Earlier this month, Mirion Medical welcomed ec² Software Solutions, expanding the company’s Nuclear Medicine and Molecular Imaging Portfolio. Featured for ec² at RSNA in booth #2101, Numa® software provides innovative DICOM and HL7 workflow and communications solutions to meet the specific needs of nuclear medicine, nuclear cardiology, Radiopharmacies, PET and PET/CT departments.

"We are thrilled to welcome ec² Software Solutions to our medical family of solutions, further expanding and strengthening our commitment to leverage ionizing radiation to support innovation in healthcare. By adding to our portfolio through acquisitions and strengthening our proven technologies, as we’ve done with our new InstadoseVUE dosimeter, we continue to build on the depth and breadth of our medical portfolio,” said Thomas Logan, Mirion CEO.

RSNA attendees can gain insights on these products and more in Mirion Medical booth #6328 at RSNA.

About Mirion

Mirion is a global leader in radiation safety, science and medicine, empowering innovations that deliver vital protection while harnessing the transformative potential of ionizing radiation across a diversity of end markets. The Mirion Technologies group provides proven radiation safety technologies that operate with precision – for essential work within R&D labs, critical nuclear facilities, and on the front lines. The Mirion Medical group solutions help enhance the delivery and ensure safety in healthcare, powering the fields of Nuclear Medicine, Radiation Therapy QA, Occupational Dosimetry, and Diagnostic Imaging. Headquartered in Atlanta (GA – USA), Mirion employs approximately 2,700 people and operates in 12 countries. Learn more at: mirion.com.

InstadoseVUE, IQphan, RapidCHECK, Captus, CRC, Sound Pro, Numa, Sun Nuclear, Capintec, Biodex and Mirion Dosimetry Services are trademarks or registered trademarks of Mirion Technologies, Inc. and/or its affiliates in the United States and/or other countries.

Contacts

For investor inquiries:
Jerry Estes
ir@mirion.com

For media inquiries:
Erin Schesny
media@mirion.com

Mirion


Release Versions

Contacts

For investor inquiries:
Jerry Estes
ir@mirion.com

For media inquiries:
Erin Schesny
media@mirion.com

More News From Mirion

Mirion Announces Second Quarter 2024 Financial Results and Updates Full Year Guidance

ATLANTA--(BUSINESS WIRE)--Mirion (“we” or the “company”) (NYSE: MIR), a global provider of radiation detection, measurement, analysis and monitoring solutions to the medical, nuclear, defense, and research end markets, today announced results for the second quarter ended June 30, 2024. “Our second quarter results were in-line with our expectations,” stated Thomas Logan, Mirion’s Chief Executive Officer. “Both segments delivered steady top-line growth and strong Adjusted EBITDA margin expansion...

Mirion Announces Earnings Release and Conference Call Date for Second Quarter 2024

ATLANTA--(BUSINESS WIRE)--Mirion (NYSE: MIR) announced today that it will release financial results for second quarter 2024 after market close on Thursday, August 1, 2024. Following the news release, the company will host a conference call the next day, Friday, August 2, 2024, at 11:00 am ET to discuss the results. Participants may access the call by dialing 1-877-407-9208 or 1-201-493-6784, and requesting to join the Mirion Technologies, Inc. earnings call. A live webcast will also be availabl...

Mirion Announces Updated Time of Presentation at Jefferies’ 2024 Global Healthcare Conference

ATLANTA--(BUSINESS WIRE)--Mirion (NYSE: MIR) announced today that its management team’s presentation at Jefferies’ 2024 Global Healthcare Conference will now begin at 3:30 PM ET on Thursday, June 6, 2024. The presentation will be webcast live at https://ir.mirion.com/news-events where a link will be displayed under the "Events and Presentations” section. An archive of the webcast will be available at the same location within twelve hours of the conclusion of the event. About Mirion Mirion (NYSE...
Back to Newsroom